儿童心脏瓣膜置换术的选择。

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Future cardiology Pub Date : 2025-01-01 Epub Date: 2025-01-09 DOI:10.1080/14796678.2024.2445402
Eli Contorno, Herra Javed, Louis Steen, John Lowery, Ahmed Zaghw, Ali Duerksen, Rodolfo Henrich-Lobo, Brian Reemtsen, T Konrad Rajab
{"title":"儿童心脏瓣膜置换术的选择。","authors":"Eli Contorno, Herra Javed, Louis Steen, John Lowery, Ahmed Zaghw, Ali Duerksen, Rodolfo Henrich-Lobo, Brian Reemtsen, T Konrad Rajab","doi":"10.1080/14796678.2024.2445402","DOIUrl":null,"url":null,"abstract":"<p><p>Heart valve replacement is indicated for children with irreparable heart valve disease. These replacements come in a variety of forms including mechanical, xenograft tissue, allograft tissue, and autograft tissue valves. These options each have unique benefits and risks profiles. Mechanical valves are the most structurally durable; however, they represent significant thrombogenic risks and require anticoagulant therapy. Xenograft and homograft tissue valves do not carry the thrombogenic risks found with mechanical valves but also do not have the structural integrity of mechanical valves. Importantly, neither of these options allows for the somatic growth, requiring serial reoperation to implant upsized valves. Autograft implantation and partial heart transplantation each allow for the implantation of growing valves; however, autografts require for either a mechanical or bioprosthetic valve to be fitted into another valve position and PHT requires immunosuppressive medication to allow for the growth of the valve. In summary, outcomes of valve implantation in the pediatric population are significantly subpar compared to the outcomes enjoyed by the adult population. To remedy this, further innovation is needed in heart valve replacement technology.</p>","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"47-52"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812425/pdf/","citationCount":"0","resultStr":"{\"title\":\"Options for pediatric heart valve replacement.\",\"authors\":\"Eli Contorno, Herra Javed, Louis Steen, John Lowery, Ahmed Zaghw, Ali Duerksen, Rodolfo Henrich-Lobo, Brian Reemtsen, T Konrad Rajab\",\"doi\":\"10.1080/14796678.2024.2445402\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Heart valve replacement is indicated for children with irreparable heart valve disease. These replacements come in a variety of forms including mechanical, xenograft tissue, allograft tissue, and autograft tissue valves. These options each have unique benefits and risks profiles. Mechanical valves are the most structurally durable; however, they represent significant thrombogenic risks and require anticoagulant therapy. Xenograft and homograft tissue valves do not carry the thrombogenic risks found with mechanical valves but also do not have the structural integrity of mechanical valves. Importantly, neither of these options allows for the somatic growth, requiring serial reoperation to implant upsized valves. Autograft implantation and partial heart transplantation each allow for the implantation of growing valves; however, autografts require for either a mechanical or bioprosthetic valve to be fitted into another valve position and PHT requires immunosuppressive medication to allow for the growth of the valve. In summary, outcomes of valve implantation in the pediatric population are significantly subpar compared to the outcomes enjoyed by the adult population. To remedy this, further innovation is needed in heart valve replacement technology.</p>\",\"PeriodicalId\":12589,\"journal\":{\"name\":\"Future cardiology\",\"volume\":\" \",\"pages\":\"47-52\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812425/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/14796678.2024.2445402\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2024.2445402","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

心脏瓣膜置换术适用于患有无法修复的心脏瓣膜疾病的儿童。这些替代物有多种形式,包括机械、异种移植组织、同种异体移植组织和自体移植组织瓣膜。这些选项都有独特的好处和风险。机械阀门在结构上最耐用;然而,它们具有显著的血栓形成风险,需要抗凝治疗。异种移植物和同种移植物组织瓣膜不具有机械瓣膜的血栓形成风险,但也不具有机械瓣膜的结构完整性。重要的是,这两种选择都不允许体细胞生长,需要连续的再手术来植入更大的瓣膜。自体移植和部分心脏移植都允许植入生长的瓣膜;然而,自体移植物需要将机械或生物假体瓣膜安装到另一个瓣膜位置,PHT需要免疫抑制药物来允许瓣膜的生长。总之,与成人相比,儿童瓣膜植入的结果明显低于正常水平。为了解决这个问题,心脏瓣膜置换技术需要进一步的创新。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Options for pediatric heart valve replacement.

Heart valve replacement is indicated for children with irreparable heart valve disease. These replacements come in a variety of forms including mechanical, xenograft tissue, allograft tissue, and autograft tissue valves. These options each have unique benefits and risks profiles. Mechanical valves are the most structurally durable; however, they represent significant thrombogenic risks and require anticoagulant therapy. Xenograft and homograft tissue valves do not carry the thrombogenic risks found with mechanical valves but also do not have the structural integrity of mechanical valves. Importantly, neither of these options allows for the somatic growth, requiring serial reoperation to implant upsized valves. Autograft implantation and partial heart transplantation each allow for the implantation of growing valves; however, autografts require for either a mechanical or bioprosthetic valve to be fitted into another valve position and PHT requires immunosuppressive medication to allow for the growth of the valve. In summary, outcomes of valve implantation in the pediatric population are significantly subpar compared to the outcomes enjoyed by the adult population. To remedy this, further innovation is needed in heart valve replacement technology.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Future cardiology
Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.80
自引率
5.90%
发文量
87
期刊介绍: Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信